CATX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Perspective Therapeutics Inc (CATX) is not a strong buy for a beginner, long-term investor at this moment. While the stock has bullish moving averages and positive analyst sentiment, the lack of recent news catalysts, poor financial performance, and absence of strong trading signals suggest waiting for a clearer entry point. The investor's impatience and preference for long-term growth do not align with the current mixed outlook.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the RSI at 41.245 is neutral, and MACD is positively contracting, indicating no strong momentum. The price is near the support level of 4.13, with resistance at 4.558.
Analyst ratings are consistently positive with raised price targets, and the company's pipeline of lead-212 radiotherapies shows potential. Sanofi's deprioritization of a competing product is also a favorable development.
The company's financials are weak, with a significant YoY revenue drop (-43.36%) and negative net income (-$25.97M). No recent news or congress trading data exists to drive sentiment. The stock's pre-market and regular market changes are negative, indicating bearish short-term sentiment.
In Q3 2025, revenue dropped by 43.36% YoY to $209,000. However, net income improved by 71.73% YoY to -$25.97M, and EPS increased by 66.67% YoY to -0.35. Gross margin remains at 100%, unchanged YoY.
Analysts are bullish, with multiple firms raising price targets recently (e.g., H.C. Wainwright to $13, UBS to $8, Piper Sandler to $16). They highlight the company's pipeline potential and reduced competition as key positives.
